Víctor Manuel González, Ph.D., General Manager & CSO
Dr Víctor M. González is researcher at the Ramon y Cajal Research Institute (IRYCIS) where is currently leading the Aptamers Research Group. PhD in Molecular Biology from the Universidad Autónoma de Madrid. He worked as postdoctoral student at the Centro de Biología Molecular “Severo Ochoa” (CSIC-UAM) in Madrid and spent two years in the Cancer Geriatric Center, University of Michigan, where he collaborated in apoptosis related projects. As a researcher in Spain he worked in the Universidad de Alcalá and the CNB (National Biotechnology Center) in Madrid. In 2002 he joined to the Ramón y Cajal Institute (IRYCIS) in Madrid and founded the Aptamers Research Group. Between 2007 and 2009 co–founded and was scientific advisor of the company Bioapter. In 2010 co-founded Aptus Biotech and become CSO of the company.
Gerónimo Fernández, Ph.D., Technical Director & Project Manager
Dr. Fernández has a PhD in Chemistry from Universidad de Alcalá de Henares. As a postodoctoral he worked in virology related applications for three years at the Gregorio Marañón Hospital (Madrid). Some important patents were granted from this research activities. Later, he worked for Dendrico, a company focused in developing dendrimers for drug delivery of nucleic acids and other therapeutic candidates. He also worked for NLife Therapeutics, a company focused in modifying and applying nucleic acids (siRNA and aptamers) in new therapies. In 2011, he joined to Aptus Biotech through the Torres Quevedo Program.
Ana García Sacristán, Ph.D., Bussiness Development & Project Manager
PhD in Biochemistry and Molecular Biology from the Universidad Complutense de Madrid. As a postdoctoral she’s worked at the IMM (Molecular Medicine Institute), Lisbon Medical School and the Astrobiology Center (CAB, CSIC-INTA). As a basic researcher she’s focused in studying nucleic acids structure, gen regulation, quality control of transcription and viral RNA. Currently, she is in charge of AptaVirus R&D projects. In 2013, he joined to Aptus Biotech through the Torres Quevedo Program.